Full Press Release Details
Life Sciences to present two studies featuring StemPrintER, a stem cell biology-based Breast Cancer Prognostic Tool during the
American Society of Clinical Oncology (ASCO) Virtual Conference
additional abstracts featuring Milciclib in treating Hepatocellular Carcinoma to be published online
York/London - May 11, 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA) ("Tiziana" or the "Company"),
a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune diseases, announces that two abstracts
on the Company's stem cell biology-based genomic tool, StemPrintER, for the prediction of disease recurrence in breast cancer
patients, will be presented at the American Society of Clinical Oncology's 2020 Virtual Conference. All abstracts, including
Abstract #1020, which compares Tiziana's product to current market leader Oncotype DX as part of a poster discussion session,
will be available online beginning May 13, 2020 beginning at 5:00 PM ET at abstracts.asco.org.
The American Society of Clinical Oncology (ASCO) Virtual Conference will be held from May 29-31, 2020.
addition, the Company will publish online two e-abstracts featuring its Miliciclib compound for the treatment of hepatocellular
carcinoma on 13 May 2020 but which will not be presented as part of the conference.
Discussion Session, Breast Cancer, Metastatic:
Session, Breast Cancer, Metastatic:
data being presented at ASCO are significant for our oncology portfolio and highlight a complementary technology for detection
of breast cancer," said Dr. Kunwar Shailubhai, CEO & CSO of Tiziana Life Sciences. "Of particular note is that
one of these studies was selected to be part of a poster discussion session during the meeting. We look forward to sharing these
critical data on our StemPrintER clinical diagnostic for ER+/HER2- breast cancer patients and its utility in potentially optimizing
therapeutic decision-making, especially in the discussion of StemPrintER relative to the current market leader, Oncotype DX."
is a multi-gene prognostic assay intended for the prediction of the risk of recurrence in luminal, estrogen receptor-positive
HER2-negative breast cancer patients, based on the detection of 20 cancer stem cell markers. The assay has been evaluated in an
initial retrospective validation study using a consecutive cohort of approximately 2,400 patients with breast cancer.
is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycin receptor kinases and Src family
kinases controlling cell growth and malignant progression of cancer. Milciclib has demonstrated safety in 316 patients with advanced
solid cancers in Phase I and II studies and shown indications of efficacy. In two completed Phase II thymic cancer trials, Milciclib
successfully increased overall survival and met both primary and secondary endpoints. While the current standard of care for hepatocellular
carcinoma (HCC), the most common liver cancer, is only effective in a small percentage of patients, Milciclib has the potential
to be broadly effective because it targets the underlying cause of disease. A unique feature of Milciclib is its ability to reduce
microRNAs, miR-221 and miR-222, that promote the formation of blood vessels (angiogenesis) to facilitate the spread of cancer
cells. Levels of these microRNAs are consistently increased in HCC patients and may contribute towards resistance to treatment
Tiziana Life Sciences
Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human
disease in oncology and immunology. In addition to Milciclib, the Company is also developing Foralumab for liver diseases. Foralumab
is the only fully human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential
application in a wide range of autoimmune and inflammatory diseases, multiple sclerosis, type-1 diabetes ("T1D"),
Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.
news and updates from Tiziana Life Sciences plc by signing up to get email alerts at https://ir.tizianalifesciences.com.
statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts
but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs;
and assumptions. Words such as anticipates,' expects,' intends,' plans,' believes,'
'seeks,' estimates,' and similar expressions are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors,
some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially
from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security
holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the
date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which
the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking
statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required
by law or by any appropriate regulatory authority.
Cerrone, Chairman and founder +44 (0)20 7495 2379
Financial Advisers LLP (Nominated adviser)
Murray / Jo Turner + 44 (0)20 7213 0883
Bossi / Fiona Conroy +44 (0)20 7601 6125